Recombinant MLANA antibody (N-Term)
Quick Overview for Recombinant MLANA antibody (N-Term) (ABIN7879617)
Target
See all MLANA AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- N-Term
-
Purpose
- Melan-A Antibody / MART-1
-
Purification
- Protein A/G affinity
-
Immunogen
- A recombinant fragment corresponding to the N-terminus of human Melan A protein was used as the immunogen for the Melan-A antibody.
-
Isotype
- IgG, kappa
-
-
-
-
Application Notes
- Optimal dilution of the Melan-A antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Aliquot the Melan-A antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- MLANA (Melan A (MLANA))
-
Alternative Name
- Melan-A
-
Background
- This antibody recognizes a protein doublet of 20-22 kDa, identified as MART-1 (Melanoma Antigen Recognized by T cells 1) or Melan-A. MART-1 is a newly identified melanocyte differentiation antigen recognized by autologous cytotoxic T lymphocytes. Seven other melanoma associated antigens recognized by autologous cytotoxic T cells include MAGE-1, MAGE-3, tyrosinase, gp100, gp75, BAGE-1, and GAGE-1. Subcellular fractionation shows that MART-1 is present in melanosomes and endoplasmic reticulum. This mAb labels melanomas and other tumors showing melanocytic differentiation. It is also a useful positive-marker for angiomyolipomas. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.
-
UniProt
- Q16655
Target
-